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Abstract
Toxoplasma gondii is an important foodborne opportunistic pathogen that causes a severe 
disease in immunocompromised patients. The pathology and immune responses associ-
ated with the ensuing disease have not been well described in strains from different parts 
of the world. The aim of the present study is to determine the IFN-γ and IL-10 variations 
and organ pathology in immunocompetent and immunocompromised mice infected 
with T. gondii isolated from a Kenyan chicken. Two groups of BALB/c mice were infected 
with T. gondii cysts and administered with dexamethasone (DXM) in drinking water. 
Other two groups: infected untreated and uninfected mice were kept as controls. The 
mice were euthanized at various time points: blood collected for serum and assayed for 
IFN-γ and IL-10 variations. After infection, significant (p<0.05) elevated levels of IFN-γ 
and IL-10 were observed. A significant decline in IFN-γ and IL-10 levels (p<0.05) was 
observed after dexamethasone treatment. Histological sections in the liver, heart, and 
spleen of the mice administered with DXM revealed various degrees of inflammation 
characterized by infiltration of inflammatory cells. The dexamethasone-treated mice pre-
sented with progressively increased (p<0.001) inflammatory responses is compared with 
the infected untreated mice.
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1. Introduction
Toxoplasmasmosis, cause by Toxoplasma gondii, is rated the most prevalent parasitic zoonotic 
disease infecting nearly 2 billion people in the world [1]. The infection may be acquired by 
oral ingestion of food or water contaminated with oocysts present in the feces of members of 
the cat family, the definitive hosts for T. gondii. Other routes of infections include ingestion of 
tissue cysts found in undercooked meat and congenitally by transplacental transmission [2].
Cases of toxoplasmosis have been reported in Kenya with the earliest study documented in 
1968 [3]. Since then, T. gondii has been detected in the general Kenyan population as well as 
susceptible groups with reduced immunity. A serological survey of 127 children revealed a sig-
nificant rise of prevalence of the T. gondii-specific antibodies from 35% in pre-school to 60% in 
the early school age group [4]. Screening results for blood donors at Kenyatta National Referral 
Hospital in Nairobi, Kenya indicated high seroprevalence [5]. Fifty four percent (54%) of HIV 
positive patients attending Kenyatta National Hospital, Nairobi had Toxoplasma specific IgG in 
contrast to 1% of the HIV negative group [6]. A clinical case report of toxoplasmosis was docu-
mented in a patient with HIV infection [7]. About 12.7% of hospitalized HIV positive patients 
with neurological complications at a private hospital in Nairobi, had T. gondii infection [8]. 
Co-infection of T. gondii and other parasites such as Toxocara canis has been investigated using 
samples from Kenyans. Toxoplasma gondii was detected in five of seven T. canis–positive sera 
from Maasailand [9]. Chunge and colleagues [10] showed that a moderate number of pregnant 
women attending a Kenyan referral hospital had T. gondii antibodies [10]. Such publications 
and clinical case reports show that there is widespread distribution toxoplamsois in Kenya.
Natural T. gondii infection has been detected in free-living and captive animals [11]. Of these 8 
of 8 (100%) captive carnivores, 14 of 19 (74%) captive herbivores, 11 of 14 (79%) free-living car-
nivores and 97 of 118 (82%) free-living herbivores were found to have Toxoplasma antibodies. 
The detection of Toxoplasma gondii in free-range chickens is a good indicator of possible risk to 
human beings. In a study carried out in Thika region, Kenya, the prevalence of T. gondii in the 
chicken was 79.0% indicating high environmental contamination with T. gondii oocysts [12]. 
In another study carried out by Adele et al. [12] in Thika region, Toxoplasma gondii oocysts 
were detected in 7.8% of the cat samples collected. In the same region of Kenya, up to 39% of 
the slaughterhouse workers were infected with T. gondii as detected using nPCR [13]. Several 
studies have shown the circulation of various strains of T. gondii in Kenya, with the most 
abundant being type II strain [14, 15].
Infection of immunologically competent persons with T. gondii most often results in asymptom-
atic infection where the parasite forms tissue cysts containing bradyzoites in a variety of organs, 
particularly the brain, heart, and skeletal muscle. However, in immunosuppressed hosts such as 
those with AIDS, organ transplantation and radiotherapy, there is a high risk for severe infection 
[16, 17]. In these individuals, the bradyzoite gets reactivated and gets transformed to tachyzoites 
which cause severe pathology in the heart, liver and spleen [18]. Cellular immunity plays key role 
in the host’s immune reaction against toxoplasmosis [19]. The macrophages and “natural killer” 
(NK) cells exert their function via a cytotoxic activity and/or the secretion of cytokines involved 
in the regulation of immune response [20]. In vivo studies have shown that IFN-γ is a major 
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cytokine, which is produced by CD4 and CD8 T cells, which mediates resistance against T. gondii 
infection [21]. Thus, IFN-γis the main type one cytokine involved in toxoplamosis, although other 
cytokines such as TNF-α, IL-18, IL-22, and the macrophage migration inhibitory factor (MIF) have 
also been reported in mediating the observed pathology [22]. As the disease progresses, some 
studies have reported that IL-10 counters the harmful effect of an exaggerated type-1 inflam-
matory response [23]. From the foregoing, it is clear that the development of a strong cellular 
immune response is critical for the control of the T. gondii infections in the intermediate hosts.
In a study carried out in Kenya, a neurological murine model of chronic toxoplasmosis in 
BALB/c was developed in BALB/c mice using T. gondii isolated from free range chicken [24]. 
The brain of toxoplasmosis infected mice showed cellular inflammatory infiltrations, neu-
ronal necrosis, and cuffing. Other studies have showed lymphocytes and plasma cells to be 
the predominant cells in brains of patients having a coinfection of HIV and toxoplasmosis 
[25]. The severity of pathology was higher in mice immunosuppressed with dexamethasone 
compared to the control groups. The findings demonstrated that a dexamethasone-induced 
reactivation of chronic toxoplasmosis may be useful development of laboratory animal model 
in outbred mice used for in vivo studies.
Despite the fact that there is a high burden of toxoplasmosis and transmission in Africa [13], there 
are no studies which have evaluated the immunopathology of Toxoplasma isolates from these 
countries. Further, there is little information available regarding the immune responses inherent 
to reactivated toxoplasmosis. Acute and chronic infections in the neurological model described 
above [24] was associated with increase in both IgM and IgG levels but following dexamethasone 
treatment, IgM levels declined but IgG levels continued on rising. The current study therefore 
sought to determine the profile of IFN-γ and IL-10, and organ pathology in immunocompetent 
and immunosuppressed mice infected with T. gondii isolated from a chicken in Kenya.
2. Materials and methods
2.1. Laboratory animals and ethical clearance
Prior to commencement of the study, all protocols and procedures used were reviewed and 
approved by the Institute of Primate Research, Institutional Animal Care and Use committee 
(Approval number: IRC/21/11). A total of 84 female BALB/c white mice were obtained from 
the rodent breeding facility Institute of Primate Research, Nairobi, Kenya. The mice were 
6–8 weeks old and weighed 20–30 g. The mice were housed under standard laboratory condi-
tions, in plastic cages (medium size cages; length 16.9 inches, width 10.5 inches, and height 
5 inches) with wood shaving bedding and nesting material. Food (Mice Pellets®, Unga Feeds 
Ltd., Kenya), and drinking water were provided ad libitum.
2.2. T. gondii isolate and expansion
The T. gondii isolate used in this study was obtained from the brain of a free range chicken 
from Thika region, Kenya [26]. Briefly, the hen was sacrificed by cervical dislocation and the 
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brain tissue collected under sterile conditions and processed for experimental infections. The 
brain was grounded and homogenized using tissue homogenizer. Enumeration of cysts was 
done as previously described [27], and the suspension was serially diluted with PBS (pH 7.2) 
to adjust to a desired final concentration of 15 tissue cysts/200 μl [24]. Three BALB/c mice were 
intraperitoneally injected each with 15 tissue cysts to allow for expansion of T. gondii cysts for 
use in experimental infection described below. The mice were monitored for 6 weeks post 
infection, euthanized using CO2, and parasites isolated as stated earlier.
Prior to commencement of experimental work, the presence of T. gondii in the chicken samples 
was determined by extracting DNA from the brain sample using a Quick-gDNA™ MiniPrep 
Kit (Zymo research, USA) and nested PCR undertaken as previously described [13, 26]. 
Secondary amplification products were electrophoresed on 1.5% agarose gel stained with 
ethidium bromide and visualized under ultraviolet (UV) light.
2.3. Experimental design
The BALB/c mice were intraperitoneally infected with 15 T. gondii cysts in a 200 μl inoculum 
[24, 28]. In the first part of the experiment, 32 infected mice in groups of four were randomly 
chosen and euthanized by concentrated CO
2
 inhalation on 3, 5 and 7 dpi for acute infection 
and 14, 21, 28, 35, 42 dpi for chronic infection. Sixteen BALB/C mice were controls and not 
infected with T. gondii.. After euthanasia, sampling for blood from the heart was done as 
previously described [23]. The liver, heart and spleen were also collected and preserved in 
10% formalin and used for histology as described below.
At 42 dpi, 48 BALB/c mice previously infected with 15 cysts each, were divided into three 
groups of 16 mice each. The mice were treated with Dexamethasone (Decadron DexPak 
PHARMA Links, India) at dosages of 2.66 mg/kg (Group 1) and 5.32 mg/kg (Group 2) daily 
in drinking water over a period of 6 weeks [24, 29, 30]. Sixteen infected nontreated mice were 
used as controls (Group 3). Another 16 uninfected control mice were given untreated water 
(Group 4). The mice were monitored daily over 6 weeks for survival analysis and any clinical 
signs and mortalities were recorded. After every 2 weeks, four mice from each group were 
serially euthanized using concentrated carbon dioxide and sampling done as previously 
described above. Mice that showed any severe clinical signs of toxoplasmosis were anesthe-
tized immediately using concentrated carbon dioxide and sampling of blood, done. The liver, 
heart and spleen were collected and preserved in 10% formalin.
2.4. IFN-γ and IL-10 levels
Serum for cytokine activities was prepared as previously described by Parasuraman et al. [31]. 
Cytokine production was evaluated using commercial ELISA kits according to the manufactur-
er’s instructions (MABTECH AB, Augustendalsvagen 19, Sweden). Briefly, each well of a 96-well 
high protein binding microtiter plate was coated with 100 μl/well of the respective monoclonal 
antibody diluted in PBS, pH 7.4 and incubated overnight at 4–8°C. The plates were washed 
twice with PBS (200 μl/well) and blocked by adding 200 μl/well of PBS with 0.05% Tween 20 
containing 0.1% BSA (incubation buffer) and incubated for 1 hour at room temperature. Serum 
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samples or recombinant mouse IFN-γ and IL-10 standards were then applied to the plates, and 
incubated for 2 h at 37°C. After washing, the respective biotinylated monoclonal antibody for 
IFN-γ and IL-10 was added and the plates incubated for an additional 1 h at 37°C. One hundred 
microliters of Streptavidin-ALP was then added to each microtiter well and incubated for 1 h at 
37°C. After washing, 100 μl of p-nitrophenyl phosphate substrate was added to each well and 
the optical density measured at 405 nm for pNPP in an ELISA reader after suitable developing 
time. Cytokine concentrations were determined by reference to standard curves generated with 
murine recombinant cytokines. The sensitivity limits of the assays were 20 pg/ml for IL-10 and 
4 pg/ml for IFN-γ as per the instructions of the manufacturer.
2.5. Histological analysis
Liver, spleen and heart were processed for paraffin embedding and sectioning. To deter-
mine the histological changes, tissue sections were stained with hematoxylin and eosin and 
observed under light microscope. The inflammation was assessed and scored histologically. 
The severity of the histopathological lesions in the heart was evaluated by grading the lesions 
using a modified random scale as previously described [32].
In the liver, the inflammatory lesions were quantified based on the degree of lymphocyte 
infiltration and hepatocyte necrosis as previously described [33]. Segments of spleen were 
scored for the enlargement of lymphocyte infiltrated areas and for the increased numbers of 
macrophages and necrotic cells previously described [34].
In these organs, the inflammatory changes were examined in two noncontinuous sections 
(40 μ distance between them) from each mouse in 25 microscopic fields using a 40× objective. 
The total inflammation score was determined from the summed scores of each mouse from 
each group or sampling time point and used for data analysis.
2.6. Data analysis
The results were entered into MS Excel program (Microsoft, USA) before being exported to 
GraphPad prism version 5.0 (GraphPad Software, USA) for statistical analysis. Statistical 
differences between the mice groups were determined by ANOVA; groups were considered 
statistically different if P ≤ 0.05.
3. Results
3.1. IFN-γ Levels
The mean of IFN-γ cytokine levels in the infected mice are as shown in Figure 1. There was 
a progressively significant (p < 0.001) increase in IFN-γ from 3.5 pg/ml (95%; CI: 2.93–4.07 at 
day 0 reaching 10.59 pg/ml, (95% CI: 9.03–12.15) at 35 dpi. The noninfected control group did 
not display any significant increase in IFN-γ cytokine levels and remained decreased at all 
time points compared to the infected group.
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Figure 2. Mean levels of IFN-γ in serum in BALB/c infected with T. gondii and after dexamethasone treatment. The 
results are expressed as the means ± SEM of 4 mice. Group 1 = T. gondii infected dexamethasone treated (2.66 mg/kg/day); 
Group 2 = T. gondii infected dexamethasone treated (5.32 mg/kg/day); Group 3 = T. gondii infected; Group 4 = Noninfected 
control.
After treatment with dexamethasone, IFN-γ productions levels progressively declined at time 
points between 42 and 84 dpi. The decline in the 2.66 mg/kg/day of dexamethasone treated 
mice (Group 1) was from 17.84 pg/ml (95% CI: 1.60–34.08) at 42 dpi to 10.02 pg/ml (95% CI: 
2.98–17.07) at 84 dpi (Figure 2).
The corresponding decline in the 2.66 mg/kg/day of dexamethasone treated mice (Group 2) 
was from 15.51 pg/ml (95% CI:−0.64–31.66) at 42 dpi to 7.89 pg/ml (95%; CI: 3.02–12.73.50) at 
Figure 1. Levels of IFN-γ in serum of BALB/c infected with T. gondii during the early (7–14 dpi) and late stages (21–35 
dpi) of infection. The data are expressed as the means ± SEM.
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84 dpi. The decrease in IFN-γ levels was associated with increased dose, although the dif-
ference between the 2 doses were not significant (P > 0.05). The IFN-γ levels in the infected 
nontreated mice (Group 3) increased from 21.48 pg/ml (95%CI: 10.59–32.38) at 42 dpi to 
26.38 pg/ml (95% CI: 20.01–32.75) at 56 dpi and thereafter, a progressive decline in IFN-γ lev-
els reaching 13.53 pg/ml (95% CI: 0.42–26.64) and 11.03 pg/ml (95% CI: 5.43–16.64) at 70 and 
84 dpi, respectively. Mice in the infected nontreated group (Group 3) maintained significantly 
(P < 0.001) increased levels of IFN-γ compared to the infected treated mice (Figure 2).
3.2. IL-10 levels
The levels of IL10 also increased following T. gondii infection. The levels significantly (P < 0.001) 
increased from 3.5 pg/ml (95%; CI: 2.93–4.07) at day 0 post-infection reaching 99.6 pg/ml (95% 
CI: 83.62–115.58) at 7 dpi and remained elevated up to day 35 dpi (119.6 pg/ml; 95%; CI: 
106.27–124.45) (Figure 3).
Following dexamethasone treatment, the levels of IL-10 maintained a downward trend 
(Figure 4). In the mice treated with 2.66 mg/kg/day of DXM, the levels ranged between 
135.66 pg/ml (95% CI: 82.79–188.54) at 42 dpi and dropped to 71.73 pg/ml (95% CI: 45.67–
97.79) at 84 dpi. In the group treated with 5.32 mg/kg/day, the IL-10 level was 116.92 pg/
ml (95% CI: 89.69–144.15) at 42 dpi and dropped to 55.59 pg/ml (95% CI: 40.77–70.43) at 84 
dpi. The infected group (group 3) recorded a decreased IL-10 concentration ranging between 
141.97 pg/ml (95% CI: 134.26–149.68) at 42 dpi and 99.71 pg/ml (95% CI: 77.16–122.27) at 84 
dpi. Mice in the infected group recorded significantly (P < 0.01) elevated IL-10 levels com-
pared to the treated groups at all time points.
3.3. Histological changes in the peripheral organs of BALB/c mice infected with T. gondii
In general, the histopathological changes in the liver, heart and spleen of infected mice 
consisted of mild-to-moderate congestion and detectable multifocal or focal inflammatory 
infiltrate. Between 3 and 14 dpi, the liver showed increased pathology characterized by 
hepatic necrosis, infiltration of lymphocytes and macrophages scattered in portal triad areas 
(Figure 5). The inflammatory scores increased from 1.2 (±0.49) at 3 dpi to 2.0 (±0.316) at 7 dpi. 
The highest inflammatory score was recorded at 14 dpi (2.8 ± 0.2) and thereafter, a progressive 
significant decline in inflammatory score (P < 0.001) at 42 dpi (1.4 ± 0.4) was observed.
Following dexamethasone treatment, the mice treated with 2.66 mg/kg/day (Group 1) and 
5.32 mg/kg/day (Group 2) of dexamethasone showed varied degrees of inflammatory responses. 
For the mice treated with 2.66 mg/kg/day of dexamethasone, an inflammatory score of 1.4 (±0.245) 
and 2.0 (±0.00) was observed between 56 and 84 dpi, respectively, while the mice treated with 
5.32 mg/kg/day (Group 2) of dexamethasone recorded an inflammatory score of 1.6 (±0.245) and 
2.6 (±0.25) at 56 and 84 dpi, respectively. On the other hand, the infected nontreated mice pre-
sented an inflammatory score of 0.6 (±0.245) at 42 dpi but did not significantly (P > 0.05 change 
with the progression of the infection maintaining at 0.8 (±0.2) at 56, 70 and 84 dpi. Although the 
treated mice presented with progressively increased inflammatory scores there was no signifi-
cant difference (P > 0.05) in the liver inflammatory response between the same groups.
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In the heart of infected mice, the histopathological lesions were relatively fewer compared 
to those in liver and were characterized by inflammatory infiltrates (Figure 6). The inflam-
matory score at 7 dpi was 1.75 (±0.25) and this was followed by a significant (P < 0.001) 
decrease reaching the lowest inflammatory score of 1.25 (±0.25) at 35 dpi. However, treat-
ment with dexamethasone markedly increased the severity and number of myocardial 
lesions in these infected animals. The toxoplasma infected group (Group 3) presented with 
Figure 4. Levels of IL-10 in serum from BALB/c mice infected with T. gondii and after dexamethasone treatment. The data are 
expressed as the means ± SEM of 4 mice. Group 1 = T. gondii infected dexamethasone treated (2.66 mg/kg/day); Group 2 = T. 
gondii infected dexamethasone treated (5.32 mg/kg/day); Group 3 = T. gondii infected; Group 4 = Noninfected mice.
Figure 3. Mean levels of IL-10 in serum of BALB/c infected with T. gondii during the early (7–14 dpi) and late stages 
(21–35 dpi) of infection before treatment. The data are expressed as the means ± SEM.
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higher inflammatory lesions at the time of treatment (day 42 dpi; P < 0.01). However, at 56, 
70 and 84 dpi, an increasing inflammatory score was noted although there was no signifi-
cant difference (P > 0.05). All the heart tissues of mice from group 1 recorded an inflamma-
tory score of 1.25 (±0.25) at 56, 70 and 84 dpi (P > 0.05) while group 2 recorded a significant 
(p < 0.01) inflammatory score of 1.25 (±0.25); 1.5 (±0.289) and 2.5 (±0.289) at 56, 70 and 84 
dpi, respectively. The uninfected control group (Groups 4) did not show any myocardial 
lesions at all time points.
The spleen was also affected by T. gondii but unlike the liver, the inflammatory response 
started from 5 dpi. The infected mice spleens from the infected treated mice presented general 
disorganization of the germinal centers at 70 dpi. The marginal zone disappeared and the lim-
its between the disorganized germinal center and the red pulp were blurred. The noninfected 
mice spleens exhibited no change in the organizational of the germinal centers.
4. Discussion
In the present study, BALB/c mice infected with T. gondii showed that IFN-γ productions 
were markedly increased after T. gondii infection. This observation is consistent with a 
Figure 5. Liver of infected and treated mice showing dense granulomas, irregularly distributed (arrows) (A) and 
infiltrations of inflammatory cells (arrows) at the portal triad (B).
Figure 6. Heart of BALB/c mice showing inflammatory cell infiltrations (arrow).
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previous study in mice by Gazzinelli et al. [35], where equally, IFN-γ levels were exceed-
ingly elevated at the disease onset. Once released, IFNγ binds to the IFNγ receptor (IFN-γR), 
which eventually leads to the activation of IFN-γ signals “signal transducer and activator of 
transcription 1” (STAT1); [36]. These factors acts on macrophages and monocytes inducing 
the transcription of various genes involved in anti-parasitic responses including production 
of toxic reactive-oxygen species [37, 38]. The high levels of IFN-γ production levels are sug-
gestive of its early involvement in parasite clearance [39]. The secretion of IFN-γ increases 
the phagocyte activity of macrophages and also triggers the conversion of tachyzoites 
into bradyzoites leading to chronicity [40, 41, 42]. The cytokine also prevents bradyzoite 
rupture, allowing long specific protection against new parasite infections and is hence 
responsible for regulation of T. gondii load and distribution in the tissues [43]. Although 
IFN-γ-dependent pro - inflammatory cytokines are essential for resistance to T. gondii infec-
tion, an over-production of inflammatory cytokine, IFN-γ can result in serious tissue dam-
age [38] . Therefore, the intensity of the immune responses mounted against T. gondii just 
like any other infection must be regulated to avoid exaggerated immune-pathologic effects 
due to excessive inflammation.
In the current study, the IFN-γ levels were significantly depressed in the dexamethasone-
treated T. gondii infected mice [44].). Dexamethasone administration have been shown to induce 
programmed cell death in developing lymphocytes. Harold et al. [45] has shown that dexa-
methasone is a potent suppressor of cytokine production in T cells. This drug, just like other 
glucocorticoids, act by binding to the glucocorticoid receptor, which blocks the expression of 
pro-inflammatory cytokines and adhesion molecules. Previous early studies done by Hunter 
et al. [20] showed that mice lacking T cells do not survive latent infection while depletion in T 
cells during the chronic phase or as a result of immunosuppression re-activates the disease [35].
In the current study, the IL-10 levels were also elevated during the acute and chronic infection 
and there was also a decline in immunosuppressed mice (42–84 dpi). This anti-inflammatory 
cytokine, has the ability to antagonize T helper 1 (Th1) responses [46]. IL-10 is considered 
to be an inhibitor of Th1 and Th2 immune responses [47, 48, 49]. Therefore, the role of 
IL-10 cytokines secreted by macrophages, monocytes, B cells, and CD4+ and CD8+ T cells 
during both the acute and the chronic phases of infection in both immunocompetent and 
immunosuppressed mice is to acts broadly on accessory cells and adaptive cells responses 
to downregulate or limit the consequences of an exaggerated inflammatory response and 
major histocompatibility complex and costimulatory molecule expression [20, 47, 50, 51]. This 
cytokine also prevents tissue immune destruction through immunomodulation [18] and has 
been identified as a factor induced by T. gondii infection [35, 52] that can contribute to the 
suppression of T cell function [53, 54].
Toxoplasma gondii infection caused different pathological manifestations as shown in this 
study. In the early infection, BALB/c mice displayed intense inflammatory lesions in the liver, 
heart as well as disorganization of the germinal centers of the spleen, suggesting a strong 
immune response in the pathogenesis of the disease. In the spleen, the white pulp appeared 
enlarged due to cellular proliferation and its limit with the red pulp started to disappear. 
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The detectable changes in the splenic architecture of the structures in the spleen of dexa-
methasone treated mice have been associated with a decreased ability to mount an immune 
response against the toxoplasma parasites [55]. Multiple mechanisms have been implicated 
in splenic disorganization, including CD8+ T cell-mediated cytolysis of infected stromal cells 
or follicular dendritic cells and marginal-zone macrophages [56].
The results of the present study showed that chronically infected nontreated mice had an 
increase in mononuclear cells organ infiltrations upon infection. The recruitment of inflam-
matory cells as was the case in these organs, is one of the most important immune mecha-
nisms induced by IFN-γ and is geared towards control of parasite multiplication. These cells 
could also be responsible for the higher levels of cytokines observed in the initial stage of T. 
gondii infection observed in the study. However, although there was a decline in the cytokine 
levels in the immunosuppressed mice, there was marked infiltration of mononuclear cells in 
the organs, resulting in myocarditis and hepatitis. This could be a reflection of reactivation 
and spread of toxoplasma parasites following decline in inflammatory response hindering the 
control and proliferation of the parasite [57].
5. Conclusions
The results of this study indicates that immunological and pathological features of T. gondii 
in immunosuppressed BALB/c mice mimic toxoplasmosis in immunosuppressed humans 
as it occurs during advanced HIV infection when CD4+ counts are low. The infection in 
immunocompetent host was associated with elevated IFN-γ and IL-10 which declined after 
immunosuppression. However, in both competent and immunocompetent mice, the patho-
logical signs evident in the study were myocarditis, hepatitis characterized by mononuclear 
cell infiltration. Splenic exhaustion characterized by loss of normal spleen architecture also 
characterized the infection.
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